HSOA journal of stem cells research, development & therapy最新文献

英文中文

Wharton´S Jelly Mesenchymal Stem Cell Therapy For Skin Wound Healing 华顿果冻间充质干细胞治疗皮肤伤口愈合

HSOA journal of stem cells research, development & therapy

Pub Date : 2020-06-23 DOI: 10.24966/srdt-2060/100037

Ana I. García-Guillén

The management of chronic wounds still remains an important unsolved problem in clinical practice. Different therapeutic approach-es, including regenerative medicine or tissue engineering strategies, have been used to ameliorate this pathology to achieve skin regeneration. Mesenchymal stem cells represent a potential therapeutic option for chronic wounds due to their differentiation, proliferation, and immunomodulatory properties. Among them, Wharton’s jelly mesenchymal stem cells from the umbilical cord are a type of ex- traembryonic stem cells that have been proven to be very effective for treating chronic wounds. These cells possess some advantages when compared to adult mesenchymal stem cells such as higher proliferation rate, multipotency, and low immunogenicity. They act as potent immunomodulators during the inflammation phase of wound healing and are also involved in replacing the damaged skin tissue. In this review we will discuss the findings obtained in different preclin ical and clinical studies performed with Wharton´s jelly mesenchymal stem cells systemically administered, implanted on a biocompatible scaffold, or using mesenchymal stem cell-derived extracellular ves- icles or their conditioned medium as possible treatments for chronic wounds

慢性伤口的处理在临床实践中仍然是一个重要的未解决的问题。不同的治疗方法，包括再生医学或组织工程策略，已被用来改善这种病理，以实现皮肤再生。间充质干细胞因其分化、增殖和免疫调节特性而成为慢性伤口的潜在治疗选择。其中，来自脐带的Wharton’s jelly间充质干细胞是一种前胚胎干细胞，已被证明对治疗慢性伤口非常有效。与成体间充质干细胞相比，这些细胞具有增殖率高、多能性强、免疫原性低等优点。它们在伤口愈合的炎症阶段作为有效的免疫调节剂，也参与替换受损的皮肤组织。在这篇综述中，我们将讨论在不同的临床前和临床研究中获得的发现，这些研究使用沃顿果冻间充质干细胞进行系统管理，植入生物相容性支架上，或使用间充质干细胞衍生的细胞外血管或其条件培养基作为慢性伤口的可能治疗方法

{"title":"Wharton´S Jelly Mesenchymal Stem Cell Therapy For Skin Wound Healing","authors":"Ana I. García-Guillén","doi":"10.24966/srdt-2060/100037","DOIUrl":"https://doi.org/10.24966/srdt-2060/100037","url":null,"abstract":"The management of chronic wounds still remains an important unsolved problem in clinical practice. Different therapeutic approach-es, including regenerative medicine or tissue engineering strategies, have been used to ameliorate this pathology to achieve skin regeneration. Mesenchymal stem cells represent a potential therapeutic option for chronic wounds due to their differentiation, proliferation, and immunomodulatory properties. Among them, Wharton’s jelly mesenchymal stem cells from the umbilical cord are a type of ex- traembryonic stem cells that have been proven to be very effective for treating chronic wounds. These cells possess some advantages when compared to adult mesenchymal stem cells such as higher proliferation rate, multipotency, and low immunogenicity. They act as potent immunomodulators during the inflammation phase of wound healing and are also involved in replacing the damaged skin tissue. In this review we will discuss the findings obtained in different preclin ical and clinical studies performed with Wharton´s jelly mesenchymal stem cells systemically administered, implanted on a biocompatible scaffold, or using mesenchymal stem cell-derived extracellular ves- icles or their conditioned medium as possible treatments for chronic wounds","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"266 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75066160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

PKM2-Mediated Glycolysis And Redox Equilibrium In Cancer Stem Cells: The Metabostemness Phenomenon 肿瘤干细胞中pkm2介导的糖酵解和氧化还原平衡:代谢现象

HSOA journal of stem cells research, development & therapy

Pub Date : 2020-06-23 DOI: 10.24966/srdt-2060/100040

S. Manolakou

Glycolysis and Redox Equilibrium in Cancer Stem Cells: The Metabostemness Phenomenon. J Stem Cell Res Dev Ther 6: 040. Abstract The discovery of novel targets in cancer cells along with the rapid development of innovative therapeutic agents against them and especially in last decade has led to better cancer survival rate. However, the existence of Cancer Stem Cells (CSCs) into the tumor col-onies has been suggested as a crucial impediment in cancer fight. Not only the self-renewal and high proliferative ability of CSCs but also the diversity of their metabolic signatures amplifies the tumor heterogeneity and treatment-resistance, defining a new hallmark of oncogenesis called metabostemness phenomenon. This phenomenon concludes several patterns of metabolic behaviour which rely on three basic phenotypes; (i) Aerobic glycolysis or Warburg effect; (ii) Reverse Warburg effect and (iii) Oxidative Phosphorylation (OX- PHOS) phenotype. Pyruvate Kinase M2 (PKM2) has been considered as the key regulator enzyme of metabolic reprogramming of CSCs as alternates itself between a dimer state, responsible for aerobic glycolysis and a tetramer state, responsible for OXPHOS pro- cedure. Several PKM2 interactions which perceive the changes of a usually oxidative microenvironment of CSCs attribute to a metabolic plasticity and as a result to survival, proliferation, metastasis and drug-resistance. Henceforth, this review highlights the evidence regarding CSCs about these PKM2-mediated interactions describing the outcome of them in terms of metabolic reprogramming and of maintenance of redox equilibrium. Thereafter, a recapitulation of molecular targeting of PKM2 and metabostemness will be attempt-ed so as to be given prominence to the development of innovative metabolic targets and therapies against the triangle “PKM2 - metabolic plasticity - oxidative scale” in CSCs.

肿瘤干细胞中的糖酵解和氧化还原平衡:代谢现象。[J] .中国生物医学工程学报，21(6):444 - 444。摘要近年来，随着肿瘤细胞靶点的不断发现和抗癌药物的快速发展，肿瘤患者的生存率不断提高。然而，肿瘤干细胞(Cancer Stem Cells, CSCs)在肿瘤集落中的存在被认为是对抗癌症的关键障碍。CSCs不仅具有自我更新和高增殖能力，而且其代谢特征的多样性扩大了肿瘤的异质性和治疗耐药性，定义了一种称为代谢现象的肿瘤发生的新标志。这种现象总结了几种依赖于三种基本表型的代谢行为模式;(i)有氧糖酵解或Warburg效应;(ii)逆转Warburg效应和(iii)氧化磷酸化(OX- PHOS)表型。丙酮酸激酶M2 (PKM2)一直被认为是CSCs代谢重编程的关键调节酶，它在二聚体状态(负责有氧糖酵解)和四聚体状态(负责OXPHOS过程)之间交替。几种PKM2相互作用感知CSCs通常氧化微环境的变化，这归因于代谢可塑性，并导致存活、增殖、转移和耐药。因此，本综述强调了关于CSCs的这些pkm2介导的相互作用的证据，这些相互作用描述了它们在代谢重编程和氧化还原平衡维持方面的结果。随后，我们将尝试对PKM2和代谢的分子靶向进行概述，以便重点开发针对CSCs中“PKM2 -代谢可塑性-氧化尺度”三角形的创新代谢靶点和治疗方法。

{"title":"PKM2-Mediated Glycolysis And Redox Equilibrium In Cancer Stem Cells: The Metabostemness Phenomenon","authors":"S. Manolakou","doi":"10.24966/srdt-2060/100040","DOIUrl":"https://doi.org/10.24966/srdt-2060/100040","url":null,"abstract":"Glycolysis and Redox Equilibrium in Cancer Stem Cells: The Metabostemness Phenomenon. J Stem Cell Res Dev Ther 6: 040. Abstract The discovery of novel targets in cancer cells along with the rapid development of innovative therapeutic agents against them and especially in last decade has led to better cancer survival rate. However, the existence of Cancer Stem Cells (CSCs) into the tumor col-onies has been suggested as a crucial impediment in cancer fight. Not only the self-renewal and high proliferative ability of CSCs but also the diversity of their metabolic signatures amplifies the tumor heterogeneity and treatment-resistance, defining a new hallmark of oncogenesis called metabostemness phenomenon. This phenomenon concludes several patterns of metabolic behaviour which rely on three basic phenotypes; (i) Aerobic glycolysis or Warburg effect; (ii) Reverse Warburg effect and (iii) Oxidative Phosphorylation (OX- PHOS) phenotype. Pyruvate Kinase M2 (PKM2) has been considered as the key regulator enzyme of metabolic reprogramming of CSCs as alternates itself between a dimer state, responsible for aerobic glycolysis and a tetramer state, responsible for OXPHOS pro- cedure. Several PKM2 interactions which perceive the changes of a usually oxidative microenvironment of CSCs attribute to a metabolic plasticity and as a result to survival, proliferation, metastasis and drug-resistance. Henceforth, this review highlights the evidence regarding CSCs about these PKM2-mediated interactions describing the outcome of them in terms of metabolic reprogramming and of maintenance of redox equilibrium. Thereafter, a recapitulation of molecular targeting of PKM2 and metabostemness will be attempt-ed so as to be given prominence to the development of innovative metabolic targets and therapies against the triangle “PKM2 - metabolic plasticity - oxidative scale” in CSCs.","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81489575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing the Therapeutic Potential of Stem Cell Therapies for Critical Limb Ischemia. 提高干细胞疗法对严重肢体缺血的治疗潜力。

HSOA journal of stem cells research, development & therapy

Pub Date : 2020-01-01 Epub Date: 2020-01-20 DOI: 10.24966/srdt-2060/100024

Hallie J Quiroz, Samantha F Valencia, Zhao-Jun Liu, Omaida C Velazquez

Peripheral Arterial Disease (PAD) is a progressive, atherosclerotic disease that at its end stage, Critical Limb Ischemia (CLI), results in severely diminished limb perfusion and causes leg pain at rest, non-healing ulcers, and tissue gangrene. Many patients with CLI fail current medical and surgical therapies and thus are deemed "no option" and require limb amputation. Novel therapies to attempt limb salvage in these "no option" patients are needed. Stem cell therapy is one therapeutic angiogenic avenue that has been tested over the last 20 years. To date, clinical trials have shown promise but with only modest improvement and none demonstrated a significant decrease in amputation rates in those treated with stem cell therapy. Thus, recent investigations into improving stem cell therapy have been the focus of our laboratory and many others. This review aims to describe recent advances in increasing the therapeutic potential of stem cell therapies for CLI.

外周动脉疾病（PAD）是一种渐进性动脉粥样硬化疾病，在其终末阶段，即严重肢体缺血（CLI）时，会导致肢体灌注严重减少，引起静息时腿部疼痛、溃疡不愈合和组织坏疽。许多肢体重度缺血患者无法接受目前的药物和手术疗法，因此被认为 "别无选择"，需要截肢。我们需要新的疗法来挽救这些 "别无选择 "的患者的肢体。干细胞疗法是在过去 20 年中进行过测试的一种血管生成治疗方法。迄今为止，临床试验已显示出希望，但改善幅度不大，没有一项试验显示干细胞疗法可显著降低截肢率。因此，改进干细胞疗法的最新研究成为我们实验室和许多其他实验室的工作重点。本综述旨在描述干细胞疗法在提高CLI治疗潜力方面的最新进展。

引用次数: 0

Human Prostate Stem Cells and Their Niche - A Comprehensive Review 人类前列腺干细胞及其生态位综述

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-11-12 DOI: 10.24966/srdt-2060/100020

R. Heer

引用次数: 0

LncRNAs Regulate the PDLSCs Osteogenic Differentiation in Periodontitis lncrna调控牙周炎患者PDLSCs成骨分化

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-11-12 DOI: 10.24966/srdt-2060/100021

Zuolin Jin

引用次数: 0

Mesenchymal Stromal Cells and Micro Fragmented Adipose Tissue: New Horizons of Effectiveness of Lipogems 间充质间质细胞和微碎片化脂肪组织:脂质体有效性的新视野

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-09-25 DOI: 10.24966/srdt-2060/100017

C. Tremolada, Image Regenerative Clinic

In the last three years there has been an explosion of published in vivo and clinical data discussing micro fragmented adipose tissue and its regenerative properties. In fact, the paracrine activity of micro fragmented adipose tissue has been well described, showing the importance of the maintenance of an intact microvascular environment of fat tissue during the processing in order to guarantee cellular activation and long-term viability there by maintaining their signaling capacity in order to effectively modulate inflammation and immune response. Lipogems®, patented in 2010 and clinically available since 2013, is a novel technology that reproducibly and simply obtains, micro fragmented adipose tissue with enhanced regenerative properties with somewhat astonishing results that are now confirmed from recent clinical trials. In this review we have summarized all the new evidence published, focusing on possible new clinical indications from intriguing new in vivo studies.

在过去的三年里，关于微碎片化脂肪组织及其再生特性的体内和临床研究数据呈爆炸式增长。事实上，微碎片化脂肪组织的旁分泌活性已经得到了很好的描述，这表明在加工过程中维持脂肪组织完整的微血管环境的重要性，通过维持其信号传导能力来保证细胞的激活和长期生存，从而有效地调节炎症和免疫反应。Lipogems®于2010年获得专利，自2013年开始临床应用，是一项可重复且简单地获得具有增强再生特性的微碎片脂肪组织的新技术，最近的临床试验证实了这一惊人的结果。在这篇综述中，我们总结了所有发表的新证据，重点是来自有趣的新的体内研究的可能的新的临床适应症。

引用次数: 6

Using Transcriptome Analysis for Redefining the in vivo Relevance of in vitro Cultured Circulating Angiogenic Cells (CACiv) 利用转录组分析重新定义体外培养循环血管生成细胞(CACiv)的体内相关性

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-09-25 DOI: 10.24966/srdt-2060/100015

B. Everaert

引用次数: 0

The Tgf-β1 Over Expression has Major Impact on Multilineage Differentiation of Mesenchymal Stromal Cells Tgf-β1过表达对间充质间质细胞多系分化有重要影响

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-09-25 DOI: 10.24966/srdt-2060/100013

H. Salkın

with a superior capacity for self-renewal, and are capable of differentiating into adipocytes, osteoblasts, chondrocytes [1,2]. In these days, MSCs have been broadly used in regenerative medicine [3]. Dental Pulp-derived Mesenchymal Stem Cells (DPSCs) have become a popular research topic in that they are similar too the rmesenchymal stem cells, easy to obtain and are used in regenerative medicine and tissue engineering [4]. In vitro and in vivo studies have been previously performed to understand the biology of DPSCs. The differentiation of mesenchymal stem cells usually involves the use of signaling factors as recombinant proteins or gene therapy that an functionally activate genes [5]. Transforming Growth Factor Beta 1 (TGF-β1) activates mainly SMAD transcription factors with complex cellular responses [6]. The superior proliferative ability and regenerative potential are primary phenotypes of MSCs [7].

具有超强的自我更新能力，能够分化为脂肪细胞、成骨细胞、软骨细胞[1,2]。近年来，间充质干细胞在再生医学领域得到了广泛的应用。牙髓源性间充质干细胞(DPSCs)因其与间充质干细胞相似，易于获得，并可用于再生医学和组织工程等领域而成为研究热点。为了了解DPSCs的生物学特性，以前已经进行了体外和体内研究。间充质干细胞的分化通常涉及使用信号因子作为重组蛋白或基因治疗来功能性激活基因[5]。转化生长因子β1 (TGF-β1)主要激活SMAD转录因子，具有复杂的细胞反应[6]。优越的增殖能力和再生潜力是MSCs[7]的主要表型。

引用次数: 0

Stem/Progenitor Cells in Skin 皮肤中的干细胞/祖细胞

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-09-25 DOI: 10.24966/srdt-2060/100016

Xusehng Wang

引用次数: 1

Recellularization Of Canine Placental Extracellular Matrix: Mesenchymal Stem Cells Applied To Tissue Bioengineering 犬胎盘细胞外基质的再细胞化:间充质干细胞在组织生物工程中的应用

HSOA journal of stem cells research, development & therapy

Pub Date : 2019-08-01 DOI: 10.1016/j.placenta.2019.06.347

G. Matias, A. C. Carreira, M. Miglino, P. Fratini, R. Barreto

引用次数: 1

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

HSOA journal of stem cells research, development & therapy

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀